Analysis and Enlightenment of Swiss Medical Insurance Access and Pricing Policy for Innovative Drugs
Objective:To meet the people's demand for excellent medicine,the paper provides reference for the optimization of medical insurance access and pricing procedures for innovative drugs in China.Methods:This paper systematically summarizes the access and pricing policies of innovative drugs in Switzerland from three dimensions:decision-making institutions,processes and standards,and analyzes the problems and shortcomings of the current policy in China.Results:Switzerland strictly examines the drugs applying for access through the health technology assessment procedure with"WWZ"as the core,and integrates the internal and external reference prices to ensure the rationality of the price.In order to encourage innovation,innovative drugs can also get an"innovation premium"higher than the reference drugs.Conclusion:We should improve the drug health technology assessment system,and give different prices or reimbursement rates to drugs with different degrees of innovation according to the evaluation results.At the same time,we should pay attention to the communication with multiple stakeholders,promote their participation in decision-making,and ensure the openness and transparency of the evaluation.
万方数据
维普
